abstract |
Compounds of formula II are described: n n n n n n n n n n n n wherein D, n, R a , R b , and R c are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient. |